SCHEMBL3330153

SCHEMBL3330153

CC(C)(C)OC(=O)NC1CCN(c2cccc3ccc(-c4cnc5cc(-c6cccnc6)ccn45)nc23)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 6/20 0.45
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
KDM4D Q6B0I6 2/20 0.43
KDR P35968 7/20 0.43
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA3 P34903 1/20 0.39
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38
NRAS P01111 1/20 0.38
LCK P06239 1/20 0.38
RET P07949 1/20 0.38
PDGFRB P09619 1/20 0.38
FLT3 P36888 1/20 0.38
CDK7 P50613 1/20 0.38
IRAK1 P51617 1/20 0.38
CCNH P51946 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3333344 0.86 CKS1B (0.42) FGFR3CKS1BSKP1SKP2KDM4D
SCHEMBL25248269 0.81 FLT3 (0.44) KDRLCKRETPDGFRBFLT3
SCHEMBL729701 0.76 KDR (0.47) FGFR3KDRFLT3
SCHEMBL729699 0.76 KDR (0.47) FGFR3KDRFLT3
SCHEMBL729700 0.76 KDR (0.47) FGFR3KDRFLT3
SCHEMBL3335188 0.74 KDR (0.46) FGFR3KDRGABRG2GABRB3GABRA3
SCHEMBL3333798 0.74 KDR (0.49) KDRFLT3
SCHEMBL3396947 0.73 KDR (0.46) KDRFLT3
SCHEMBL28450722 0.73 DRD2 (0.52) CKS1BSKP1SKP2PDE10A
SCHEMBL729619 0.73 KDR (0.57) FGFR3KDRGABRG2GABRB3GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-06-10 US disclosed
EP-2139888-A2 IMIDAZOÝ1,2-A¨PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-01-06 EP disclosed
WO-2008121687-A2 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 FGFR3 140/4885CKS1B 423/4885SKP1 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.